Exosomes loaded with programmed death ligand-1 promote tumor growth by immunosuppression in osteosarcoma

par Lei Zhang, Lili Xue, Yanjuan Wu, Qilong Wu, Hongwei Ren, Xiang Song
Publié 2021

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas

par Utpal Kumar, Michael Leonard Anthony, Rishabh Sahai, Ankur Mittal, Prashant Durgapal, Sanjeev Kishore
Publié 2021

Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report

par Tae‐Hun Kim, Sun Hyo Park, Ilseon Hwang, Jin Hee Lee, Jin Hee Kim, Hae Won Kim, Hyun Jung Kim
Publié 2021

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis

par Yixi Zhang, Bin La, Baosheng Liang, Yangchun Gu
Publié 2021

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases

par Xin Cai, Huajie Zhan, Yuguang Ye, Jinjin Yang, Minghui Zhang, Jing Li, Yuan Zhuang
Publié 2021

Spatiotemporally co-delivery of triple therapeutic drugs via HA-coating nanosystems for enhanced immunotherapy

par Chaoqun Ma, Yichao Duan, Chaohui Wu, Erjuan Meng, Pingping Li, Zhenzhong Zhang, Chunhua Zang, Xueling Ren
Publié 2021

Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma

par Virginia Liberini, Marco Rubatto, Riccardo Mimmo, Roberto Passera, Francesco Ceci, Paolo Fava, Luca Tonella, Giulia Polverari, Adriana Lesca, Marilena Bellò, Vincenzo Arena, Simone Ribero, Pietro Quaglino, Désirée Deandreis
Publié 2021

The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target

par Lingxiao Ye, Zhengxin Zhu, Xiaochuan Chen, Haoran Zhang, Jiaqi Huang, Shengxian Gu, Xiaoyin Zhao
Publié 2021

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations

par Andrea Palicelli, Martina Bonacini, Stefania Croci, Cristina Magi-Galluzzi, Sofia Cañete-Portillo, Alcides Chaux, Alessandra Bisagni, Eleonora Zanetti, Dario De Biase, Beatrice Melli, Francesca Sanguedolce, Magda Zanelli, Maria Paola Bonasoni, Loredana De Marco, Alessandra Soriano, Stefano Ascani, Maurizio Zizzo, Carolina Castro Ruiz, Antonio De Leo, Guido Giordano, Matteo Landriscina, Giuseppe Carrieri, Luigi Cormio, Daniel M. Berney, Jatin Gandhi, Giacomo Santandrea, Maria Carolina Gelli, Alessandro Tafuni, Moira Ragazzi
Publié 2021

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical an...

par Andrea Palicelli, Martina Bonacini, Stefania Croci, Cristina Magi-Galluzzi, Sofia Cañete-Portillo, Alcides Chaux, Alessandra Bisagni, Eleonora Zanetti, Dario De Biase, Beatrice Melli, Francesca Sanguedolce, Moira Ragazzi, Maria Paola Bonasoni, Alessandra Soriano, Stefano Ascani, Maurizio Zizzo, Carolina Castro Ruiz, Antonio De Leo, Guido Giordano, Matteo Landriscina, Giuseppe Carrieri, Luigi Cormio, Daniel M. Berney, Daniel Athanazio, Jatin Gandhi, Alberto Cavazza, Giacomo Santandrea, Alessandro Tafuni, Magda Zanelli
Publié 2021

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade

par Otgontuya Ganbaatar, Satoru Konnai, Tomohiro Okagawa, Yutaro Nojima, Naoya Maekawa, Yoshiki Ichikawa, Atsushi Kobayashi, Tomoyuki Shibahara, Yojiro Yanagawa, Hidetoshi Higuchi, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata, Kazuhiko Ohashi
Publié 2021

KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer

par Yohei Sekino, Quoc Thang Pham, Kohei Kobatake, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Tetsutaro Hayashi, Hikaru Nakahara, Kazuhiro Sentani, Naohide Oue, Wataru Yasui, Jun Teishima, Nobuyuki Hinata
Publié 2021

PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells

par Xu S, Cui F, Huang D, Zhang D, Zhu A, Sun X, Cao YM, Ding S, Wang Y, Gao E, Zhang F
Publié 2018

Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study

par Ayoub NM, Fares M, Marji R, Al Bashir SM, Yaghan RJ
Publié 2021

Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cance...

par Louis Boafo Kwantwi, Shujing Wang, Wenjun Zhang, Weidong Peng, Zeyu Cai, Youjing Sheng, Han Xiao, Xian Wang, Qiang Wu
Publié 2021

Tumor-Associated Exosomes: A Potential Therapeutic Target for Restoring Anti-Tumor T Cell Responses in Human Tumor Microenvironments

par Gautam N. Shenoy, Maulasri Bhatta, Richard B. Bankert
Publié 2021

Kaposi’s Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes

par Kurtis M. Host, Sarah R. Jacobs, John A. West, Zhigang Zhang, Lindsey M. Costantini, Charles M. Stopford, Dirk P. Dittmer, Blossom Damania
Publié 2017

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities

par Xiaopei Cui, Xiaopei Cui, Huifeng Jia, Hong Xin, Lei Zhang, Shi Chen, Simin Xia, Xue Li, Wei Xu, Xiaofang Chen, Yujie Feng, Xiaoyue Wei, Haijia Yu, Yanting Wang, Yifan Zhan, Xiangyang Zhu, Xiangyang Zhu, Xuemei Zhang
Publié 2021

Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicul...

par Yasuhito Mihashi, Shoichi Kimura, Hiromi Iwasaki, Yumi Oshiro, Yasushi Takamatsu, Shigeto Kawauchi, Shohei Shimajiri, Kenji Ishizuka, Morishige Takeshita
Publié 2021

Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibito...

par Wen Dong, Pengfei Lei, Xin Liu, Qin Li, Xiangyang Cheng
Publié 2021